Centre suspends 3 scientists over fake Remdesivir sale in Covid 2nd wave

The development comes at a time when the Central Drugs Standard Control Organisation has been accused of a bribery scandal allegedly involving a senior Biocon executive

Mansukh L. Mandaviya
Mansukh L. Mandaviya
BS Web Team New Delhi
2 min read Last Updated : Jul 02 2022 | 11:12 AM IST
Union health minister Mansukh Mandaviya suspended three senior scientists at the Central Drugs Laboratory (CDL) and also pulled up the Drugs Controller General of India, V G Somani, after an investigation revealed that fake Remdesivir antivirals were sold during the second wave of the Coronavirus (Covid-19) pandemic, according to a report in Mint. 

The CDL is India's apex lab, responsible for conducting quality checks on drugs and vaccines. It has now come to light that the three suspended scientists deliberately delayed carrying out similar checks on Remdesivir, said government officials. The development comes at a time when a bribery allegations have rocked the Central Drugs Standard Control Organisation (CDSCO). 

Hailed as a wonder drug at one point in time, the scientists submitted their findings on Remdesivir to CDSCO after the sample's expiry date. In 2020, the drug regulator granted restricted emergency use of Remdesivir for Coronavirus patients. An injectible, Remdesivir was first used by former US president Donald Trump after he contracted the virus before the WHO issued a warning against its use.

In an interview to Mint, one of the govt officials stated, "CDL Kolkata is an apex lab for quality check of life-saving drugs, medicines and vaccines. They have to submit a quality compliance report to the CDSCO in a timely manner. However, during the covid pandemic, such reports were allowed to be submitted in a fast-track manner." He further added that in the case of Remdesivir, the report was delayed intentionally for a period of nine months.

The health ministry received a tip off regarding the same last month, following which an investigation was ordered by Union health minister Mandaviya. During the investigation, it was revealed that Remdesivir sample was spurious and the three suspended scientists were trying to conceal the report. 

A strict warning has now also been issued to the DGCI, directing that such incidents should not happen again. Further, the health ministry has also ordered V G Somani to regularly monitor the work of central labs, those responsible for the quality check of life-saving drugs.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Mansukh Lal Mandaviyacentral governmentScientistsRemdesivir

Next Story